Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
8
5
6
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
Tongji NADs Cohort
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
National, Multicentric Registry Study on Neuroimmunological Diseases in China
MS-ResearchBiomarkerS
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve